MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
of marketable...
$56,209K
Proceeds from issuance of
common stock under...
$36K
Net cash (used in)
provided by investing...
$8,466K
Net cash provided by
financing activities
$36K
Canceled cashflow
$47,743K
Net decrease in cash
and cash...
-$3,956K
Canceled cashflow
$8,502K
Stock-based compensation
expense
$5,029K
Non-cash operating lease
expense
$478K
Prepaid expenses and
other assets
-$438K
Accounts payable,
accrued expenses and...
$328K
Depreciation and
amortization
$205K
Purchase of marketable
securities
$47,743K
Net cash used in
operating activities
-$12,458K
Canceled cashflow
$6,478K
Net loss
-$17,580K
Accretion of discounts on
marketable securities
$735K
Operating lease
liabilities
-$621K
Back
Back
Cash Flow
source: myfinsight.com
RAPT Therapeutics, Inc. (RAPT)
RAPT Therapeutics, Inc. (RAPT)